Previous 10 | Next 10 |
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year wi...
Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides NNVC +11%. Travere Therapeutics TVTX +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix CMRX -58%. Eliem Therapeutics ELYM -29%. Humacyte (HUMA) -20%. Va...
NanoViricides (NYSE:NNVC) stock rose premarket on May 16 after the company said it began drug development to fight recent cases of severe pediatric hepatitis. The company said it began a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 T...
Rattler Midstream RTLR +14% Diamondback Energy to buy Rattler Midstream in all-stock deal. Spirit Airlines SAVE +14% on new tender offer from JetBlue. AgriFORCE Growing Systems (AGRI) +15%. NanoViricides (NNVC) +14% reports that it has begun drug development to combat...
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe ...
Gainers: Better Therapeutics (BTTX) +34%. Great Elm (GEG) +9%. Nuvectis Pharma (NVCT) +8%. Viatris (VTRS) +5%. BioNTech (BNTX) +3%. Losers: TherapeuticsMD (TXMD) -30%. Sutro Biopharma (STRO) -12%. NanoViricides (NNVC) -12%. RedHill Biopharma (RDHL)...
NanoViricides (NYSE:NNVC) provided an update on its oral and injectable drug programs for coronavirus. The company said it was close to completing an Investigators Medicinal Product Dossier which is required as part of a clinical trial application for its lead drug candidate NV-CoV-2 to ...
SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform is providing an update on its clinical-trial ready Coronavirus Oral and In...
NanoViricides press release (NYSE:NNVC): FQ2 GAAP EPS of -$0.17. The Company reported that it had approximately $17.35M of cash, cash equivalents as of December 31, 2022. The Company believes it has sufficient funds for initial human clinical trials of at least one of its drug candidate...
SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for second quarter of its 2022 fiscal ...
News, Short Squeeze, Breakout and More Instantly...
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says...
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, ...